Management of Peyronie's disease after collagenase (Xiaflex®) - Abstract

Although the prevalence of Peyronie's disease (PD) is reported to be 3-9% in men, the true prevalence is likely higher due to under-reporting.

Many treatment modalities have been described for PD with varying degrees of success. In this article, we review and summarize the current literature pertaining to all pharmacotherapies (oral, intralesional, iontophoresis, and topical) and minimally invasive treatments available for PD (vacuum, traction device, shock wave therapy, and radiation treatment). Additionally, we discuss emerging therapies for PD that are still in pre-clinical development, including stem cell therapy.

Written by:
Alwaal A, Hussein AA, Zaid UB, Lue TF.   Are you the author?
University of California, San Francisco Box 0738 1600 Divisadero St., MZ Bldg A, Room A609 San Francisco, CA 94143.

Reference: Curr Drug Targets. 2014 Nov 14. Epub ahead of print.


PubMed Abstract
PMID: 25395101

UroToday.com Peyronie's Section